HK1033831A1 - Method for producing fludarabin phosphate lithium, sodium, potassium, calcium and magnesium salts, purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99.5% pure - Google Patents

Method for producing fludarabin phosphate lithium, sodium, potassium, calcium and magnesium salts, purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99.5% pure

Info

Publication number
HK1033831A1
HK1033831A1 HK01103119A HK01103119A HK1033831A1 HK 1033831 A1 HK1033831 A1 HK 1033831A1 HK 01103119 A HK01103119 A HK 01103119A HK 01103119 A HK01103119 A HK 01103119A HK 1033831 A1 HK1033831 A1 HK 1033831A1
Authority
HK
Hong Kong
Prior art keywords
producing
fludarabin phosphate
fludarabin
phosphate
potassium
Prior art date
Application number
HK01103119A
Other languages
English (en)
Inventor
Ulf Tilstam
Thomas Schmitz
Klaus Nickisch
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7852365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1033831(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of HK1033831A1 publication Critical patent/HK1033831A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/19—Purine radicals with arabinosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01103119A 1997-12-11 2001-05-02 Method for producing fludarabin phosphate lithium, sodium, potassium, calcium and magnesium salts, purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99.5% pure HK1033831A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19756289 1997-12-11
PCT/EP1998/007651 WO1999029710A2 (de) 1997-12-11 1998-11-30 Reinigungsverfahren zur herstellung von fludarabin-phosphat

Publications (1)

Publication Number Publication Date
HK1033831A1 true HK1033831A1 (en) 2001-09-28

Family

ID=7852365

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01103119A HK1033831A1 (en) 1997-12-11 2001-05-02 Method for producing fludarabin phosphate lithium, sodium, potassium, calcium and magnesium salts, purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99.5% pure

Country Status (21)

Country Link
US (2) US6046322A (da)
EP (1) EP1047704B2 (da)
JP (2) JP4261051B2 (da)
KR (2) KR20050085937A (da)
AT (2) ATE231880T1 (da)
AU (1) AU739574B2 (da)
CA (1) CA2313486A1 (da)
CZ (1) CZ296366B6 (da)
DE (2) DE29825173U1 (da)
DK (1) DK1047704T4 (da)
ES (1) ES2190136T5 (da)
HK (1) HK1033831A1 (da)
HU (1) HU226997B1 (da)
IL (1) IL136283A (da)
NO (1) NO315324B1 (da)
PL (1) PL195712B1 (da)
SI (1) SI1047704T2 (da)
SK (1) SK283475B6 (da)
TW (1) TW424093B (da)
WO (1) WO1999029710A2 (da)
ZA (1) ZA9811338B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1047704T2 (sl) 1997-12-11 2008-02-29 Bayer Schering Pharma Ag Postopek za pripravo fludarabin-fosfat litijevih,natrijevih, kalijevih, kalcijevih in magnezijevihsoli, cistilni postopek za pripravo fludarabin-fosfata in fludarabin-fosfat z vsaj 99,5 % cistoto
KR100381930B1 (ko) * 2000-03-16 2003-04-26 (주)바이오니아 유전자 변형 농산물 검출방법 및 검출용 프라이머
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
EP1542531A4 (en) * 2002-05-24 2011-01-05 Sicor Inc Aqueous fludarabine phosphorus composition
EP1464708A1 (en) * 2003-04-03 2004-10-06 Pro. Bio. Sint. S.p.A. A process for the preparation of fludarabine phosphate from 2-fluoroadenine
US7698201B2 (en) * 2006-09-14 2010-04-13 The Prudential Insurance Company Of America Financial instrument utilizing an optional benefit election
CN103040855B (zh) * 2012-12-28 2014-05-14 海南锦瑞制药股份有限公司 一种磷酸氟达拉滨的药物组合物及其制备方法
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN109265505A (zh) * 2018-09-12 2019-01-25 连云港杰瑞药业有限公司 一种磷酸氟达拉滨异构体杂质的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756704A (fr) 1969-09-26 1971-03-01 Parke Davis & Co Procede de production du 5'-phosphate de 9-(beta-d- arabinofuranosyl) adenine et de ses sels
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
DE3323621A1 (de) 1982-07-08 1984-03-01 Yamasa Shoyu K.K., Choshi, Chiba Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier
US5110919A (en) 1989-12-04 1992-05-05 Ash Stevens, Inc. Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates
CA2064723C (en) * 1990-06-27 1997-09-09 Peter Blumbergs Process for the preparation of 9-beta-d-arabinofuranosyl-2-fluoroadenine 5'-phosphate
US5602246A (en) 1992-11-25 1997-02-11 Schering Aktiengesellschaft Process for the preparation of fludarabine or fludarabine phosphate from guanosine
FR2701027B1 (fr) * 1993-02-01 1997-07-18 Warner Lambert Co Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate.
DE19543052A1 (de) * 1995-11-06 1997-05-07 Schering Ag Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren
IT1276126B1 (it) 1995-11-14 1997-10-27 Archimica Spa Procedimento per la preparazine di 9-((2-idrossietossi)metil) guanina
SI1047704T2 (sl) 1997-12-11 2008-02-29 Bayer Schering Pharma Ag Postopek za pripravo fludarabin-fosfat litijevih,natrijevih, kalijevih, kalcijevih in magnezijevihsoli, cistilni postopek za pripravo fludarabin-fosfata in fludarabin-fosfat z vsaj 99,5 % cistoto
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs

Also Published As

Publication number Publication date
IL136283A0 (en) 2001-05-20
CZ20002159A3 (cs) 2000-09-13
ES2190136T5 (es) 2008-03-01
CZ296366B6 (cs) 2006-02-15
JP4261051B2 (ja) 2009-04-30
CA2313486A1 (en) 1999-06-17
KR20050085937A (ko) 2005-08-29
HUP0100169A1 (hu) 2001-11-28
ATE231880T1 (de) 2003-02-15
HU226997B1 (en) 2010-04-28
EP1047704A2 (de) 2000-11-02
KR20010032919A (ko) 2001-04-25
NO20002962L (no) 2000-06-09
HUP0100169A3 (en) 2002-04-29
EP1047704B1 (de) 2003-01-29
US7547776B1 (en) 2009-06-16
PL195712B1 (pl) 2007-10-31
AT8617U1 (de) 2006-10-15
DE59807096D1 (de) 2003-03-06
DK1047704T3 (da) 2003-06-23
SI1047704T1 (en) 2004-02-29
IL136283A (en) 2006-10-31
NO20002962D0 (no) 2000-06-09
PL341659A1 (en) 2001-04-23
US6046322A (en) 2000-04-04
JP2001525418A (ja) 2001-12-11
TW424093B (en) 2001-03-01
KR100532898B1 (ko) 2005-12-05
WO1999029710A3 (de) 1999-09-10
ES2190136T3 (es) 2003-07-16
AU739574B2 (en) 2001-10-18
EP1047704B2 (de) 2007-11-07
AU2155099A (en) 1999-06-28
ZA9811338B (en) 1999-06-10
SI1047704T2 (sl) 2008-02-29
JP2009040797A (ja) 2009-02-26
DE29825173U1 (de) 2005-12-22
SK283475B6 (sk) 2003-08-05
DK1047704T4 (da) 2008-03-25
WO1999029710A2 (de) 1999-06-17
NO315324B1 (no) 2003-08-18
SK8872000A3 (en) 2001-03-12

Similar Documents

Publication Publication Date Title
AU4329297A (en) Combined cycle waste heat recovery system
GB2312670B (en) Process for producing calcium carbonate particles having size of 0.1 to 1.0mm
HK1033831A1 (en) Method for producing fludarabin phosphate lithium, sodium, potassium, calcium and magnesium salts, purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99.5% pure
DE69932620D1 (de) Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
CA2209848A1 (en) Pharmaceutical and dietary composition containing sodium, potassium, magnesium and calcium ions and enzyme activators
AU2076395A (en) Method for making chewable tablets based on troxerutine, calcium carbonate, calcium phosphate, arginine aspartate, arginine glutamate, amoxicillin, a combination of calcium carbonate and magnesium carbonate, and a combination of aluminium hydroxide and magnesium hydroxide
JP2001521062A5 (da)
EP1124757A4 (en) PROCESS FOR PREPARING POTASSIUM AND SODIUM SULPHATE CALIUM SULPHATE
AU5329399A (en) Methods of purifying lithium salts
AU5370599A (en) Method for producing highly pure libf4
AU3030097A (en) Method for producing an industrial aqueous sodium chloride solution
ITMI941543A0 (it) Procedimento per la purificazione dell'idrossido di magnesio
AU4679097A (en) Process for regenerating sodium sulphide from the sodium sulphate which forms in treating lead past from exhausted batteries
NZ318374A (en) Method for the production of magnesium pyridoxal-5'-phosphate glutamate
GB2291414B (en) Process for the manufacture of anhydrous sodium carbonate
AU5593298A (en) Process for preparing calcium carbonate which contains low concentrations of non-calcium metals
WO2000076454A3 (fr) Compositions therapeutiques a usage ophtalmique et compositions therapeutiques destinees au traitement des lesions cerebrales centrales
HUP9801312A3 (en) Process for producing 3,3-dimethyl-butyric acid
GB9425071D0 (en) Chondrocyte cell lines
ZA977515B (en) Aggregate crystals of phosphoric acid/lysine/magnesium composite salt and process for producing the same.
UA10198A (uk) Гастроентерологічний лікарський засіб "капсекол"
IL124044A0 (en) Process for recovering lithium other metals and salts from brines
PL317497A1 (en) Method of obtaining n,n,n,n',n',n',-hexabutyl-1,6-hexamethylene diammonium bromide
IT1291694B1 (it) Procedimento per la produzione di solfato di potassio dalle soluzioni geotermiche di cesano
IL123602A0 (en) Salts of 2,3,4,5-Tetrahydro-1H-3-Benzazepine compounds

Legal Events

Date Code Title Description
PF Patent in force
AM Amended specification (according sect 146 of patent law)

Free format text: METHOD FOR PRODUCING FLUDARABIN PHOSPHATE LITHIUM, SODIUM, POTASSIUM CALCIUM AND MAGNESIUM SALTS, PURIFICATION METHOD FOR PRODUCING FLUDARABIN PHOSPHATE AND FLUDARABIN PHOSPHATE WHICH IS AT LEAST 99,5% PURE

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171130